Core Viewpoint - Athira Pharma Inc. is making significant strides in its development pipeline by acquiring rights to lasofoxifene, a drug in a Phase 3 trial for metastatic breast cancer, which is expected to enhance its market position and growth potential [1][2]. Group 1: Acquisition Details - Athira has secured an exclusive global license (excluding Asia and certain Middle Eastern countries) from Sermonix Pharmaceuticals for the development and commercialization of lasofoxifene [2]. - As part of the agreement, Athira will issue a pre-funded warrant to purchase approximately 5.5 million shares at an exercise price of $0.001 per share, along with potential payments of up to $100 million based on commercialization or annual net sales milestones [3]. Group 2: Financing and Development Plans - The company announced a $90 million upfront financing through private placement of common stock and warrants, which could provide an additional $146 million if the warrants are exercised, aimed at supporting the development of lasofoxifene through key clinical and regulatory milestones [4]. - The net proceeds from the financing will be utilized for the development of lasofoxifene for treatment-resistant metastatic breast cancer, other clinical assets, and general corporate purposes [5]. Group 3: Market Performance - Following the announcement, Athira Pharma's stock surged by 74.49% to $7.22, reaching a new 52-week high, indicating strong market confidence in the company's future prospects [5].

Core Viewpoint - Olema Pharmaceuticals has announced a new clinical trial collaboration with Pfizer to evaluate the combination of palazestrant and atirmociclib in treating metastatic breast cancer, aiming to establish palazestrant as a potential backbone endocrine therapy [1][2] Group 1: Clinical Trial Collaboration - The collaboration involves a Phase 1b/2 study to assess the safety and combinability of palazestrant and atirmociclib in patients with ER+/HER2- metastatic breast cancer [1][2] - Pfizer will supply atirmociclib for the study, while Olema will lead the trial [2] - This marks Olema's second clinical trial agreement with Pfizer, following a previous agreement in November 2020 [3] Group 2: Product and Pipeline Information - Olema's lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective ER degrader, currently in a Phase 3 trial called OPERA-01 [4][5] - Palazestrant has received FDA Fast Track designation for treating ER+/HER2- metastatic breast cancer that has progressed after endocrine therapy [5] - The company is also developing OP-3136, a KAT6 inhibitor, which is in a Phase 1 clinical study [4] Group 3: Future Plans and Expectations - The new study is expected to involve approximately 35 patients, with initiation anticipated in the second half of 2025 [6] - Successful results from this study could inform a pivotal Phase 3 trial for the combination therapy in the frontline metastatic breast cancer setting [6]